Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Independence Bank of Kentucky

Independence Bank of Kentucky boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 216 shares of the biopharmaceutical company’s stock after purchasing an additional 30 shares during the quarter. Independence Bank of Kentucky’s holdings in Regeneron Pharmaceuticals were worth $154,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. International Assets Investment Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares in the last quarter. Worldquant Millennium Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $127,489,000. KBC Group NV lifted its stake in Regeneron Pharmaceuticals by 296.7% in the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after purchasing an additional 102,198 shares in the last quarter. Icon Wealth Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 18,342.0% during the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after purchasing an additional 75,569 shares during the last quarter. Finally, State Street Corp grew its position in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Bank of America reissued an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. BMO Capital Markets decreased their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $1,004.57.

Regeneron Pharmaceuticals Trading Down 1.5 %

REGN opened at $672.98 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a one year low of $666.25 and a one year high of $1,211.20. The company has a market cap of $73.95 billion, a P/E ratio of 16.65, a PEG ratio of 1.62 and a beta of 0.10. The business’s 50-day simple moving average is $720.81 and its 200-day simple moving average is $922.87.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.